Pharmacotherapy to sustain the fully remitted state. (Q34783161)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

review article

1 reference

title

Pharmacotherapy to sustain the fully remitted state (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

0 references

Sidney Kennedy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

Roger McIntyre

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

Angelo Fallu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

Raymond Lam

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

Journal of Psychiatry & Neuroscience

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

269-280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

12 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Evolution of remission as the new standard in the treatment of depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Are Two Antidepressant Mechanisms Better Than One?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

The Clinical Course of Unipolar Major Depressive Disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Efficacy of venlafaxine in depressive illness in general practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Management of recurrent depression.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Future imperfect: the long-term outcome of depression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Continuation drug therapy for major depressive episodes: how long should it be maintained?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Recognition and management of depression in general practice: consensus statement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Antidepressants in clinical practice: limitations of assessment methods and drug response

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Relapse of depression in primary care. Rate and clinical predictors

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Cost utility analysis of maintenance treatment for recurrent depression.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=161661

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

26 October 2018

1 reference

12 December 2020

The course of affective disorders

1 reference

12 December 2020

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

1 reference

12 December 2020

Recovery From Major Depression

1 reference

12 December 2020

Remission and Residual Symptomatology in Major Depression

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate

1 reference

12 December 2020

Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy

1 reference

12 December 2020

Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients

1 reference

12 December 2020

A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression

1 reference

12 December 2020

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

1 reference

12 December 2020

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome

1 reference

12 December 2020

Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis

1 reference

12 December 2020

Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression

1 reference

12 December 2020

Continuation ECT: relapse prevention in affective disorders

1 reference

12 December 2020

Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression

1 reference

12 December 2020

Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

1 reference

12 December 2020

Meta‐analysis of randomized, double‐blind, dacebo‐controlled, efficacy and safety studies of mirtazapine versus amitripcyline in major depression

1 reference

12 December 2020

Residual symptoms after partial remission: an important outcome in depression

1 reference

12 December 2020

Timing of Onset of Antidepressant Response With Fluoxetine Treatment

1 reference

12 December 2020

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

1 reference

12 December 2020

Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate

1 reference

12 December 2020

Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12174736 AND SRC:MED&resulttype=core&format=json

12 November 2019

PubMed publication ID

12174736

1 reference